<?xml version="1.0" encoding="UTF-8"?><rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/"><channel><title>CytoCares | wechat-feeds</title><link>http://MzAxNjQ3NjI4MA.favicon.privacyhide.com/favicon.ico</link><description>为您传递细胞治疗相关行业信息与技术进展，共同促进国内免疫治疗技术发展与行业繁荣。</description><managingEditor> (hellodword)</managingEditor><pubDate>Mon, 07 Jun 2021 19:56:05 +0800</pubDate><image><url>http://MzAxNjQ3NjI4MA.favicon.privacyhide.com/favicon.ico</url><title>CytoCares | wechat-feeds</title><link>http://MzAxNjQ3NjI4MA.favicon.privacyhide.com/favicon.ico</link><width>64</width><height>64</height></image><item><title>CAR-T治疗癌症的最新综述</title><link>https://mp.weixin.qq.com/s/euMI49D5L-yN7JvXydvK6Q</link><description></description><content:encoded><![CDATA[CAR-T治疗癌症的最新综述]]></content:encoded><pubDate>Mon, 07 Jun 2021 19:54:58 +0800</pubDate></item><item><title>抗体药物动态-20210607</title><link>https://mp.weixin.qq.com/s/hR187GWLRf192YClCGb6Ug</link><description></description><content:encoded><![CDATA[抗体药物动态-20210607]]></content:encoded><pubDate>Mon, 07 Jun 2021 19:54:58 +0800</pubDate></item><item><title>DMF备案全能核酸酶，为生物制品解决核酸残留困扰</title><link>https://mp.weixin.qq.com/s/9LHPPv5-ioYQQUjH_RIQwg</link><description></description><content:encoded><![CDATA[DMF备案全能核酸酶，为生物制品解决核酸残留困扰]]></content:encoded><pubDate>Fri, 04 Jun 2021 19:51:03 +0800</pubDate></item><item><title>VEGFR-2单抗的进阶多面杀癌之路</title><link>https://mp.weixin.qq.com/s/77pOjJ_XbUR6HlLyWYJMYw</link><description></description><content:encoded><![CDATA[VEGFR-2单抗的进阶多面杀癌之路]]></content:encoded><pubDate>Fri, 04 Jun 2021 19:51:03 +0800</pubDate></item><item><title>四种靶向肿瘤相关巨噬细胞的策略</title><link>https://mp.weixin.qq.com/s/ZmpdW9Enbxlz_8NRiLMleQ</link><description></description><content:encoded><![CDATA[四种靶向肿瘤相关巨噬细胞的策略]]></content:encoded><pubDate>Thu, 03 Jun 2021 19:08:44 +0800</pubDate></item><item><title>抗体药物动态-20210603</title><link>https://mp.weixin.qq.com/s/2mAjdfeikyCcRyJQb8wZ0g</link><description></description><content:encoded><![CDATA[抗体药物动态-20210603]]></content:encoded><pubDate>Thu, 03 Jun 2021 19:08:44 +0800</pubDate></item><item><title>CAR-T治疗中的细胞因子释放综合征与相关神经毒性</title><link>https://mp.weixin.qq.com/s/urDOaWCN5X-fuZEF4AOvtw</link><description></description><content:encoded><![CDATA[CAR-T治疗中的细胞因子释放综合征与相关神经毒性]]></content:encoded><pubDate>Wed, 02 Jun 2021 19:11:31 +0800</pubDate></item><item><title>抗体药物动态-20210602</title><link>https://mp.weixin.qq.com/s/1UHhbOmo0ddkgumsoAxumQ</link><description></description><content:encoded><![CDATA[抗体药物动态-20210602]]></content:encoded><pubDate>Wed, 02 Jun 2021 19:11:31 +0800</pubDate></item><item><title>IL7融合蛋白临床疗效初现</title><link>https://mp.weixin.qq.com/s/QRXj5WvG1JsMz6oi90UycQ</link><description></description><content:encoded><![CDATA[IL7融合蛋白临床疗效初现]]></content:encoded><pubDate>Tue, 01 Jun 2021 18:36:09 +0800</pubDate></item><item><title>重磅！FDA加速批准AMG510上市，KRAS-“不可成药”靶点的逆袭之路</title><link>https://mp.weixin.qq.com/s/p_t2-GCYYOrIp6phFEn6ug</link><description></description><content:encoded><![CDATA[重磅！FDA加速批准AMG510上市，KRAS-“不可成药”靶点的逆袭之路]]></content:encoded><pubDate>Mon, 31 May 2021 19:02:11 +0800</pubDate></item><item><title>抗体药物动态-20210531</title><link>https://mp.weixin.qq.com/s/Fg-XyZ1Tmfa-irjQxEQ06w</link><description></description><content:encoded><![CDATA[抗体药物动态-20210531]]></content:encoded><pubDate>Mon, 31 May 2021 19:02:11 +0800</pubDate></item><item><title>FDA发布双特异性抗体研发指南</title><link>https://mp.weixin.qq.com/s/UVmaa51E7YGs-h7MdqiXHA</link><description></description><content:encoded><![CDATA[FDA发布双特异性抗体研发指南]]></content:encoded><pubDate>Thu, 27 May 2021 19:03:44 +0800</pubDate></item><item><title>抗体药物动态-20210527</title><link>https://mp.weixin.qq.com/s/hD3uWVamP6RZ2V3SM_uo8g</link><description></description><content:encoded><![CDATA[抗体药物动态-20210527]]></content:encoded><pubDate>Thu, 27 May 2021 19:03:44 +0800</pubDate></item><item><title>记忆CD8+T细胞分类：表型与功能</title><link>https://mp.weixin.qq.com/s/hNpuQDZ6O0rOgfQc12TnIg</link><description></description><content:encoded><![CDATA[记忆CD8+T细胞分类：表型与功能]]></content:encoded><pubDate>Wed, 26 May 2021 19:08:25 +0800</pubDate></item><item><title>TACA靶向治疗进展：CAR-T和双抗</title><link>https://mp.weixin.qq.com/s/Pzet9gHqZ32mx7Qki2-XPw</link><description></description><content:encoded><![CDATA[TACA靶向治疗进展：CAR-T和双抗]]></content:encoded><pubDate>Tue, 25 May 2021 18:47:00 +0800</pubDate></item><item><title>抗体药物动态-20210525</title><link>https://mp.weixin.qq.com/s/OU4rFNYmz84COrh0EYwarQ</link><description></description><content:encoded><![CDATA[抗体药物动态-20210525]]></content:encoded><pubDate>Tue, 25 May 2021 18:47:00 +0800</pubDate></item><item><title>TROP-2 ADC药物临床实验总览</title><link>https://mp.weixin.qq.com/s/HXI_LF-dwQz3T3coWY90yg</link><description></description><content:encoded><![CDATA[TROP-2 ADC药物临床实验总览]]></content:encoded><pubDate>Thu, 20 May 2021 19:01:11 +0800</pubDate></item></channel></rss>